aspirin has been researched along with Left Ventricular Hypertrophy in 15 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a subgroup analysis in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study to determine whether aspirin interacted with the properties of losartan, an angiotensin-II receptor antagonist." | 9.11 | The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fossum, E; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Moan, A; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 7.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| " A total of 154 untreated hypertensive patients, aged 40 to 66 years, with World Health Organization stage I or II hypertension and left ventricular hypertrophy, were randomized to receive placebo, candesartan (32 mg), each of these plus aspirin (300 mg/d), or the same preparations in a reverse order, for 3 weeks, with a 3-week washout period between treatments." | 5.14 | Candesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trial. ( Chiariello, M; De Rosa, ML, 2009) |
| "We conducted a subgroup analysis in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study to determine whether aspirin interacted with the properties of losartan, an angiotensin-II receptor antagonist." | 5.11 | The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fossum, E; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Moan, A; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 3.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| "To study platelet aggregation (PA) in patients with left ventricular hypertrophy (LVH) in essential hypertension (EH) and hypertrophic cardiomyopathy (HTCM), and to assess aspirin treatment effects." | 3.70 | [Platelet aggregation in patients with various forms of left ventricular hypertrophy and its changes at long-term follow-up and treatment]. ( Gabbasov, ZA; Iurenev, AP; Riazanov, AS, 2000) |
| "Concentric left ventricular hypertrophy after MI, defined as increased cross-sectional area of transversally cut Gomori stained myocytes, was indicated by almost double myocyte size (P<0." | 1.32 | Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts. ( Saxena, PR; Schoemaker, RG; Van Kerckhoven, R; van Veghel, R, 2004) |
| "At autopsy, cerebral amyloid angiopathy (CAA) was found." | 1.29 | Fatal hemorrhage during anticoagulation of cardioembolic infarction: role of cerebral amyloid angiopathy. ( Bogousslavsky, J; Janzer, R; Melo, TP; Regli, F, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 10 (66.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Steinberg, BA | 1 |
| Kim, S | 1 |
| Piccini, JP | 1 |
| Fonarow, GC | 1 |
| Lopes, RD | 1 |
| Thomas, L | 1 |
| Ezekowitz, MD | 1 |
| Ansell, J | 1 |
| Kowey, P | 1 |
| Singer, DE | 1 |
| Gersh, B | 1 |
| Mahaffey, KW | 1 |
| Hylek, E | 1 |
| Go, AS | 1 |
| Chang, P | 1 |
| Peterson, ED | 1 |
| Yin, Z | 1 |
| Wang, X | 1 |
| Zhang, L | 1 |
| Zhou, H | 1 |
| Wei, L | 1 |
| Dong, X | 1 |
| Gitau, SC | 1 |
| Li, X | 1 |
| Zhao, D | 1 |
| Guo, Z | 1 |
| Liang, H | 1 |
| Qian, M | 1 |
| Lv, L | 1 |
| Li, T | 1 |
| Xu, B | 1 |
| Wang, Z | 1 |
| Zhang, Y | 1 |
| Xu, C | 1 |
| Lu, Y | 1 |
| Du, Z | 1 |
| Shan, H | 1 |
| Yang, B | 1 |
| De Rosa, ML | 1 |
| Chiariello, M | 1 |
| Van Kerckhoven, R | 1 |
| van Veghel, R | 1 |
| Saxena, PR | 1 |
| Schoemaker, RG | 1 |
| Wu, R | 1 |
| Laplante, MA | 1 |
| De Champlain, J | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Sidorenko, BA | 1 |
| Kiktev, VG | 1 |
| Batyraliev, TA | 1 |
| Pershukov, IV | 1 |
| Higashikuni, Y | 1 |
| Sata, M | 1 |
| Nagai, R | 1 |
| Fossum, E | 1 |
| Moan, A | 1 |
| Kjeldsen, SE | 1 |
| Devereux, RB | 1 |
| Julius, S | 1 |
| Snapinn, SM | 1 |
| Edelman, JM | 1 |
| de Faire, U | 1 |
| Fyhrquist, F | 1 |
| Ibsen, H | 1 |
| Kristianson, K | 1 |
| Lederballe-Pedersen, O | 1 |
| Lindholm, LH | 1 |
| Nieminen, MS | 1 |
| Omvik, P | 1 |
| Oparil, S | 1 |
| Wedel, H | 1 |
| Dahlöf, B | 1 |
| Weissmann, N | 1 |
| Manz, D | 1 |
| Buchspies, D | 1 |
| Keller, S | 1 |
| Mehling, T | 1 |
| Voswinckel, R | 1 |
| Quanz, K | 1 |
| Ghofrani, HA | 1 |
| Schermuly, RT | 1 |
| Fink, L | 1 |
| Seeger, W | 1 |
| Gassmann, M | 1 |
| Grimminger, F | 1 |
| Jalil, MA | 1 |
| Horiuchi, M | 1 |
| Wakamatsu, M | 1 |
| Li, MX | 1 |
| Begum, L | 1 |
| Suzuki, K | 1 |
| Kobayashi, K | 1 |
| Oka, T | 1 |
| Saheki, T | 1 |
| Pfeffer, MA | 1 |
| Braunvald, Iu | 1 |
| Moĭe, LA | 1 |
| Basta, L | 1 |
| Kaddi, TE | 1 |
| Dévis, BR | 1 |
| Geltman, EM | 1 |
| Goldman, S | 1 |
| Fleĭker, GS | 1 |
| Melo, TP | 1 |
| Bogousslavsky, J | 1 |
| Regli, F | 1 |
| Janzer, R | 1 |
| Riazanov, AS | 1 |
| Gabbasov, ZA | 1 |
| Iurenev, AP | 1 |
| Kiberd, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[NCT01165710] | 10,179 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for aspirin and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Cardiovascular risk reduction in renal transplantation. Strategies for success.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Comorbidity; Cost-Benefit | 2002 |
3 trials available for aspirin and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Candesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aspirin; Benzimidazol | 2009 |
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atenolol; Drug | 2005 |
[Effect of captopril on mortality and morbidity in patients with dysfunction of the left ventricle after myocardial infarction. Results on survival and hypertrophic studies].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Captopril; Cardiac Output, Low | 1993 |
11 other studies available for aspirin and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2013 |
Aspirin Attenuates Angiotensin II-induced Cardiomyocyte Hypertrophy by Inhibiting the Ca(2+)/Calcineurin-NFAT Signaling Pathway.
Topics: Angiotensin II; Animals; Animals, Newborn; Aspirin; Atrial Natriuretic Factor; Calcineurin; Calcium; | 2016 |
Acetyl salicylic acid attenuates cardiac hypertrophy through Wnt signaling.
Topics: Animals; Aspirin; beta Catenin; Cells, Cultured; Cyclooxygenase Inhibitors; Disease Models, Animal; | 2015 |
Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Blood Pressure; Capillaries; Captopril; | 2004 |
Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Aorta; Aspirin; Body Weight; Cells, | 2004 |
[Stroke and other tromboembolic complications in atrial fibrillation. Part I. Prevalence and risk factors].
Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Chronic Disease; Cros | 2004 |
Reversible left ventricular hypertrophy after tako-tsubo-like cardiomyopathy.
Topics: Aged; Aspirin; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Chest Pain; Drug Therapy | 2005 |
Congenital erythropoietin over-expression causes "anti-pulmonary hypertensive" structural and functional changes in mice, both in normoxia and hypoxia.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aspirin; Blood Pressure | 2005 |
Attenuation of cardiac hypertrophy in carnitine-deficient juvenile visceral steatosis (JVS) mice achieved by lowering dietary lipid.
Topics: Animals; Aspirin; Carnitine; Diet; Dinoprost; Disease Models, Animal; Dose-Response Relationship, Dr | 2006 |
Fatal hemorrhage during anticoagulation of cardioembolic infarction: role of cerebral amyloid angiopathy.
Topics: Aged; Aspirin; Cerebral Amyloid Angiopathy; Cerebral Cortex; Cerebral Hemorrhage; Cerebral Infarctio | 1993 |
[Platelet aggregation in patients with various forms of left ventricular hypertrophy and its changes at long-term follow-up and treatment].
Topics: Aspirin; Disease Progression; Echocardiography; Electrocardiography, Ambulatory; Follow-Up Studies; | 2000 |